Compare Piramal Healthcare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs IPCA LABS - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES IPCA LABS PIRAMAL ENTERPRISES/
IPCA LABS
 
P/E (TTM) x -30.9 30.3 - View Chart
P/BV x 1.1 9.4 11.2% View Chart
Dividend Yield % 2.2 0.1 1,699.8%  

Financials

 PIRAMAL ENTERPRISES   IPCA LABS
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
IPCA LABS
Mar-19
PIRAMAL ENTERPRISES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,3031,042 316.9%   
Low Rs1,797590 304.5%   
Sales per share (Unadj.) Rs716.5298.6 239.9%  
Earnings per share (Unadj.) Rs79.735.0 227.7%  
Cash flow per share (Unadj.) Rs107.949.4 218.3%  
Dividends per share (Unadj.) Rs28.003.00 933.3%  
Dividend yield (eoy) %1.10.4 298.7%  
Book value per share (Unadj.) Rs1,477.5247.1 597.9%  
Shares outstanding (eoy) m184.45126.35 146.0%   
Bonus/Rights/Conversions ISESOS-  
Price / Sales ratio x3.62.7 130.2%   
Avg P/E ratio x32.023.3 137.2%  
P/CF ratio (eoy) x23.616.5 143.2%  
Price / Book Value ratio x1.73.3 52.3%  
Dividend payout %35.18.6 409.9%   
Avg Mkt Cap Rs m470,292103,108 456.1%   
No. of employees `0007.813.4 58.2%   
Total wages/salary Rs m22,5047,874 285.8%   
Avg. sales/employee Rs Th16,899.42,807.0 602.0%   
Avg. wages/employee Rs Th2,877.7585.8 491.3%   
Avg. net profit/employee Rs Th1,879.9329.0 571.4%   
INCOME DATA
Net Sales Rs m132,15337,732 350.2%  
Other income Rs m3,128577 542.3%   
Total revenues Rs m135,28138,309 353.1%   
Gross profit Rs m66,2906,901 960.6%  
Depreciation Rs m5,2021,824 285.1%   
Interest Rs m44,097189 23,369.1%   
Profit before tax Rs m20,1195,465 368.2%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,042 826.1%   
Profit after tax Rs m14,7014,422 332.4%  
Gross profit margin %50.218.3 274.3%  
Effective tax rate %42.819.1 224.4%   
Net profit margin %11.111.7 94.9%  
BALANCE SHEET DATA
Current assets Rs m122,74223,778 516.2%   
Current liabilities Rs m310,81010,975 2,832.0%   
Net working cap to sales %-142.333.9 -419.4%  
Current ratio x0.42.2 18.2%  
Inventory Days Days23104 22.2%  
Debtors Days Days3966 58.9%  
Net fixed assets Rs m116,90420,368 574.0%   
Share capital Rs m369253 146.0%   
"Free" reserves Rs m272,16130,971 878.8%   
Net worth Rs m272,53031,224 872.8%   
Long term debt Rs m270,1961,409 19,183.3%   
Total assets Rs m856,26145,507 1,881.6%  
Interest coverage x1.530.0 4.9%   
Debt to equity ratio x1.00 2,197.8%  
Sales to assets ratio x0.20.8 18.6%   
Return on assets %6.910.1 67.8%  
Return on equity %5.414.2 38.1%  
Return on capital %12.417.3 71.7%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m15,20017,308 87.8%   
Fx outflow Rs m4,8896,266 78.0%   
Net fx Rs m10,31211,042 93.4%   
CASH FLOW
From Operations Rs m-115,9754,923 -2,355.9%  
From Investments Rs m-8,265-1,563 528.8%  
From Financial Activity Rs m107,525-1,832 -5,869.3%  
Net Cashflow Rs m-16,6501,528 -1,089.9%  

Share Holding

Indian Promoters % 52.9 45.9 115.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 11.4 35.1%  
FIIs % 26.6 25.3 105.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 17.4 94.8%  
Shareholders   93,274 36,892 252.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   CIPLA  SANOFI INDIA  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Crashed 600 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended their session deep in the red.

Related Views on News

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 0.3% (Market Updates)

Oct 28, 2020 | Updated on Oct 28, 2020

IPCA LABS share price has hit an all time high at Rs 2,456 (up 2.5%). The BSE HEALTHCARE Index is up by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 2.5%) and SANOFI INDIA (up 0.8%). The top losers include ABBOTT INDIA and ERIS LIFESCIENCES LIMITED .

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

Why ITC and not HUL is my Idea of a Good Investment Right Now(Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 28, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS